Goldman Sachs Bucks Consensus, Upgrades Intuitive Surgical

Goldman Sachs has broken ranks with the bearish consensus on Intuitive Surgical (ISRG), upgrading the stock to Buy in a move that contrasts with recent downgrades from Deutsche Bank and Bank of America. The stock, one of the most punished large-cap healthcare names this year, has declined roughly 28% in 2026.

Rating Change

Goldman Sachs analysts raised their rating from Neutral to Buy, though no new price target was disclosed in the available report. This comes after Deutsche Bank slashed its target and Bank of America trimmed its rating.

Analyst Rationale

Goldman sees the steep decline as creating an attractive entry point, especially given that the maker of the da Vinci surgical robot continues to grow revenue. The analysts believe the market has overreacted to near-term headwinds, while fundamentals remain intact.

Context

Despite the stock's slide, Intuitive Surgical has posted rising revenue, suggesting the selloff may be overdone. Most other analysts have taken a cautious stance, making Goldman's upgrade a contrarian call.

What to Make of It

Goldman's upgrade signals confidence in Intuitive's long-term growth prospects, but investors should weigh this against regulatory risks and potential competition. The decision ultimately depends on individual risk tolerance and investment horizon.